Patients’ characteristics | Group A (n = 79) | Group B (n = 61) | p-value |
---|---|---|---|
Age, median (IQR) years | 69 (62–75) | 72 (64–76) | 0.56 |
Male, n (%) | 41 (52) | 42 (69) | 0.043 |
BMI, median (IQR) kg/m2 | 25 (22–28) | 26 (24–29) | 0.58 |
Current or former smoker, n (%) | 58 (73) | 47 (77) | 0.62 |
FEV1, median (IQR) % of predicted | 99 (83–112) | 106 (90–119) | 0.16 |
COPD, n (%) | 15 (19) | 15 (25) | 0.42 |
Cardiac comorbidity, n (%) | 24 (30) | 14 (23) | 0.33 |
Diabetes, n (%) | 11 (14) | 11 (18) | 0.51 |
Previous malignancy, n (%) | 29 (37) | 17 (28) | 0.27 |
Pleural adhesiolysis, n (%) | 21 (31) | 19 (37) | 0.51 |
Lower lobe lobectomy, n (%) | 22 (28) | 31 (51) | 0.005 |
Number of excised lymph nodes, median (IQR) | 8 (6–11) | 9 (5–13) | 0.20 |
Intraoperative blood loss ≥100 ml, n (%) | 15 (23) | 14 (33) | 0.26 |
Tumor size, median (IQR) cm | 1.8 (1.5–2.8) | 1.9 (1.5–3.0) | 0.76 |
Tumor histology, n (%) | 0.76 | ||
Adenocarcinoma | 52 (66) | 45 (74) | |
Squamous cell carcinoma | 12 (15) | 9 (15) | |
Neuroendocrine tumor | 12 (15) | 5 (8) | |
Other histologies | 3 (4) | 2 (3) | |
Pathological stage, n (%) | 0.80 | ||
I | 60 (76) | 49 (80) | |
II | 15 (19) | 8 (13) | |
III | 4 (5) | 4 (7) |